S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
PriceSmart Could Be the Smartest Buy of the Year
Carmax Returns to the Bargain Basement: Buy the Dip? 
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
PriceSmart Could Be the Smartest Buy of the Year
Carmax Returns to the Bargain Basement: Buy the Dip? 
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
PriceSmart Could Be the Smartest Buy of the Year
Carmax Returns to the Bargain Basement: Buy the Dip? 
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
PriceSmart Could Be the Smartest Buy of the Year
Carmax Returns to the Bargain Basement: Buy the Dip? 
NASDAQ:CLDX

Celldex Therapeutics (CLDX) Stock Price, News & Analysis

$40.87
+1.68 (+4.29%)
(As of 04/11/2024 ET)
Today's Range
$39.03
$41.67
50-Day Range
$35.27
$51.88
52-Week Range
$22.11
$53.18
Volume
595,235 shs
Average Volume
793,062 shs
Market Capitalization
$2.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.00

Celldex Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
61.5% Upside
$66.00 Price Target
Short Interest
Bearish
11.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Celldex Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.85) to ($3.36) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.78 out of 5 stars

Medical Sector

2560th out of 2,793 stocks

Diagnostic Substances Industry

34th out of 36 stocks

CLDX stock logo

About Celldex Therapeutics Stock (NASDAQ:CLDX)

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

CLDX Stock Price History

CLDX Stock News Headlines

CLDX Celldex Therapeutics, Inc.
CLDX Aug 2024 70.000 call
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
CLDX Aug 2024 50.000 call
CLDX Apr 2024 65.000 call
CLDX Apr 2024 40.000 call
CLDX Jan 2025 15.000 put
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
CLDX Jan 2025 30.000 put
CLDX Jan 2025 70.000 call
CLDX Mar 2024 50.000 put
Celldex Therapeutics: Q4 Earnings Insights
See More Headlines
Receive CLDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
4/11/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CLDX
CUSIP
15117B10
Employees
160
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$66.00
High Stock Price Target
$90.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+61.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-141,430,000.00
Net Margins
-2,054.46%
Pretax Margin
-2,054.76%

Debt

Sales & Book Value

Annual Sales
$6.88 million
Book Value
$9.08 per share

Miscellaneous

Free Float
53,833,000
Market Cap
$2.28 billion
Optionable
Optionable
Beta
1.49

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives


CLDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Celldex Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CLDX shares.
View CLDX analyst ratings
or view top-rated stocks.

What is Celldex Therapeutics' stock price target for 2024?

5 brokers have issued 12 month target prices for Celldex Therapeutics' shares. Their CLDX share price targets range from $27.00 to $90.00. On average, they anticipate the company's stock price to reach $66.00 in the next year. This suggests a possible upside of 61.5% from the stock's current price.
View analysts price targets for CLDX
or view top-rated stocks among Wall Street analysts.

How have CLDX shares performed in 2024?

Celldex Therapeutics' stock was trading at $39.66 at the beginning of the year. Since then, CLDX shares have increased by 3.1% and is now trading at $40.87.
View the best growth stocks for 2024 here
.

Are investors shorting Celldex Therapeutics?

Celldex Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 6,560,000 shares, an increase of 11.2% from the March 15th total of 5,900,000 shares. Based on an average daily volume of 952,500 shares, the days-to-cover ratio is currently 6.9 days.
View Celldex Therapeutics' Short Interest
.

When is Celldex Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CLDX earnings forecast
.

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping analysts' consensus estimates of ($0.76) by $0.19. The biopharmaceutical company earned $4.13 million during the quarter, compared to the consensus estimate of $1.20 million. Celldex Therapeutics had a negative trailing twelve-month return on equity of 41.06% and a negative net margin of 2,054.46%.

What ETFs hold Celldex Therapeutics' stock?

ETFs with the largest weight of Celldex Therapeutics (NASDAQ:CLDX) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) and ALPS Medical Breakthroughs ETF (SBIO).SPDR S&P Biotech ETF (XBI).

When did Celldex Therapeutics' stock split?

Celldex Therapeutics shares reverse split on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Diane C Young, Elizabeth Crowley, Freddy A Jimenez, Samuel Bates Martin and Sarah Cavanaugh.
View institutional ownership trends
.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLDX) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners